Literature DB >> 12456287

Absence of evidence for differences in the dose-response for cancer and non-cancer endpoints by acute injury status in the Japanese atomic-bomb survivors.

Mark P Little1.   

Abstract

PURPOSES: To ascertain possible evidence for radiosensitive subgroups in the Japanese atomic-bomb survivors.
MATERIALS AND METHODS: Time- and age-adjusted relative risk models were fitted to the Japanese atomic-bomb survivor mortality data, taking account of the modifying effects of acute injury status and adjusting for random dosimetric errors.
RESULTS: For leukaemia, there were statistically significantly higher relative risks among those persons reporting either epilation (two-sided p=0.03) or burns (two-sided p=0.02), but after adjustment is made for the effects of dosimetric error these results become statistically non-significant (two-sided p>0.05) For all other endpoints (cancers other than leukaemia, benign neoplasms, cardiovascular disease, non-cancer and non-cardiovascular disease) there were no statistically significant modifying effects on relative risk of acute injury status, whether or not adjustment is made for the effects of dosimetric error.
CONCLUSIONS: Apart from leukaemia, there are generally no indications for cancer or other disease endpoints of variations in dose-response by acute injury status. The increased risks observed for leukaemia among those reporting epilation or burns are much diminished after adjustment for dosimetric error, and so there is no strong evidence of a sensitive subgroup within the Life Span Study cohort.

Entities:  

Mesh:

Year:  2002        PMID: 12456287     DOI: 10.1080/0955300021000013803

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  8 in total

Review 1.  A review of non-cancer effects, especially circulatory and ocular diseases.

Authors:  Mark P Little
Journal:  Radiat Environ Biophys       Date:  2013-08-01       Impact factor: 1.925

2.  Possible selection effects for radiation risk estimates in Japanese A-bomb survivors: reanalysis of acute radiation symptoms data.

Authors:  Nezahat Hunter; Colin R Muirhead; Wei Zhang
Journal:  Radiat Environ Biophys       Date:  2006-03-25       Impact factor: 1.925

3.  Lifetime Mortality Risk from Cancer and Circulatory Disease Predicted from the Japanese Atomic Bomb Survivor Life Span Study Data Taking Account of Dose Measurement Error.

Authors:  Mark P Little; David Pawel; Munechika Misumi; Nobuyuki Hamada; Harry M Cullings; Richard Wakeford; Kotaro Ozasa
Journal:  Radiat Res       Date:  2020-09-16       Impact factor: 2.841

4.  Leukaemia and myeloid malignancy among people exposed to low doses (<100 mSv) of ionising radiation during childhood: a pooled analysis of nine historical cohort studies.

Authors:  Mark P Little; Richard Wakeford; David Borrego; Benjamin French; Lydia B Zablotska; M Jacob Adams; Rodrigue Allodji; Florent de Vathaire; Choonsik Lee; Alina V Brenner; Jeremy S Miller; David Campbell; Mark S Pearce; Michele M Doody; Erik Holmberg; Marie Lundell; Siegal Sadetzki; Martha S Linet; Amy Berrington de González
Journal:  Lancet Haematol       Date:  2018-07-17       Impact factor: 18.959

Review 5.  Radiation and circulatory disease.

Authors:  Mark P Little
Journal:  Mutat Res Rev Mutat Res       Date:  2016-07-30       Impact factor: 5.657

6.  Threshold and other departures from linear-quadratic curvature in the non-cancer mortality dose-response curve in the Japanese atomic bomb survivors.

Authors:  Mark P Little
Journal:  Radiat Environ Biophys       Date:  2004-06-19       Impact factor: 1.925

7.  Shared dosimetry error in epidemiological dose-response analyses.

Authors:  Daniel O Stram; Dale L Preston; Mikhail Sokolnikov; Bruce Napier; Kenneth J Kopecky; John Boice; Harold Beck; John Till; Andre Bouville
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

Review 8.  Low dose radiation and circulatory diseases: a brief narrative review.

Authors:  Mark P Little; Steven E Lipshultz
Journal:  Cardiooncology       Date:  2015-11-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.